VRTX34 Stock Overview A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More details
Rewards Risk Analysis No risks detected for VRTX34 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Vertex Pharmaceuticals Incorporated Competitors Price History & Performance
Summary of share price highs, lows and changes for Vertex Pharmaceuticals Historical stock prices Current Share Price US$617.48 52 Week High US$748.45 52 Week Low US$496.00 Beta 0.37 1 Month Change -11.35% 3 Month Change -3.05% 1 Year Change 24.52% 3 Year Change 97.08% 5 Year Change 180.42% Change since IPO 262.45%
Recent News & Updates
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Nov 05
Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024 Oct 11
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Aug 02 See more updates
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Nov 05
Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024 Oct 11
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Aug 02
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain Jul 31 Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations Jul 16
Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Jun 22
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders. May 21
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director May 16
Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024 May 08
Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older Apr 27
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion. Apr 11
Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024 Apr 10
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024 Apr 05 Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older Feb 23
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Feb 13
Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis Feb 07
Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024 Feb 06
Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain Jan 30
Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024 Jan 18
Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia Jan 17
Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi Jan 10
Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Dec 16
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy Dec 14 CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States
Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director Dec 06
Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older Nov 30
Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 Nov 24
Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY Nov 17
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation Oct 18
Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023 Oct 11
Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors Oct 06
Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5 Sep 16
Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Aug 30
Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine Aug 04
Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old Jul 06
Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions Jun 24
Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Jun 10
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Jun 09
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares. Feb 08
Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference Nov 04
Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022 Oct 28
Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022 Oct 14
Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency Oct 12
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 Sep 28
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 10
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 09
Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months Sep 03
Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022 Aug 05
Vertex Advances VX-548 in Acute and Neuropathic Pain Jul 23
Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022 Jul 19
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 13
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 12
Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes Jul 06
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Jun 11
Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA Jun 09
Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial Jun 01
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 25
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 24
Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director May 19
Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022 May 06
Vertex Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 05, 2022 Apr 22
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for TRIKAFTA in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation Apr 21
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022 Apr 08
Vertex Pharmaceuticals Incorporated Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain Apr 01
Vertex Pharmaceuticals Incorporated Announces Reimbursement Agreement in Australia for TRIKAFTA Mar 28
Vertex Pharmaceuticals Incorporated Provides Full Year 2022 Financial Guidance Jan 27
Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) Jan 12
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis Dec 02
Vertex Pharmaceuticals Incorporated Announces Its Supplement to a New Drug Submission for PrKALYDECO Sep 24
Vertex Pharmaceuticals Incorporated Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis Aug 27
Vertex Pharmaceuticals Incorporated Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain Jul 20
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $1,500 million worth of its shares. Jun 25
Health Canada Grants Marketing Authorization for Vertex Pharmaceuticals Incorporated TRIKAFTA® Jun 19 Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations Jun 10
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress May 13
Vertex Pharmaceuticals Incorporated Provides Earnings Guidance for the Fiscal Year 2021 Apr 30
Vertex Pharmaceuticals Incorporated Announces European Commission Approval for Kaftrio in Combination with Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older with At Least One F508del Mutation in the CFTR Gene Apr 29
Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development Apr 27
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes Mar 12
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations Jan 28
Vertex Pharmaceuticals Incorporated to Report Q4, 2020 Results on Feb 01, 2021 Jan 23
Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Accepted for Priority Review by Health Canada Dec 29 Skyhawk Therapeutics, Inc and Vertex Pharmaceuticals Incorporated Establish A Strategic Collaboration to Discover and Develop Novel Small Molecules That Modulate Rna Splicing for Serious Diseases
Taysha Gene Therapies Names Kathy Reape and Laura Sepp-Lorenzino to Board of Directors Dec 10
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine Dec 06
Vertex Announces European Commission Approval for SYMKEVI® (Tezacaftor/Ivacaftor) with Kalydeco® (Ivacaftor) for Eligible Children with Cystic Fibrosis Ages 6-11 Years Nov 27 Shareholder Returns VRTX34 BR Biotechs BR Market 7D -0.3% -0.9% -1.1% 1Y 24.5% -4.6% -14.9%
See full shareholder returns
Return vs Industry: VRTX34 exceeded the BR Biotechs industry which returned -3.6% over the past year.
Return vs Market: VRTX34 exceeded the BR Market which returned -14.8% over the past year.
Price Volatility Is VRTX34's price volatile compared to industry and market? VRTX34 volatility VRTX34 Average Weekly Movement 5.7% Biotechs Industry Average Movement 8.9% Market Average Movement 5.1% 10% most volatile stocks in BR Market 9.7% 10% least volatile stocks in BR Market 3.0%
Stable Share Price: VRTX34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: VRTX34's weekly volatility (6%) has been stable over the past year.
About the Company Founded Employees CEO Website 1989 5,400 Reshma Kewalramani www.vrtx.com
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Show more Vertex Pharmaceuticals Incorporated Fundamentals Summary How do Vertex Pharmaceuticals's earnings and revenue compare to its market cap? VRTX34 fundamental statistics Market cap R$650.41b Earnings (TTM ) -R$2.96b Revenue (TTM ) R$65.65b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VRTX34 income statement (TTM ) Revenue US$10.63b Cost of Revenue US$4.93b Gross Profit US$5.69b Other Expenses US$6.17b Earnings -US$479.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.86 Gross Margin 53.59% Net Profit Margin -4.52% Debt/Equity Ratio 0%
How did VRTX34 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 08:47 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Vertex Pharmaceuticals Incorporated is covered by 75 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
Show 72 more analysts 
